Skip to main content

06-30-2021 | ADA 2021 | Conference coverage | News

News in brief

Semaglutide 2.4 mg reduces progression to type 2 diabetes

Author: Alba Ruzafa


medwireNews: Taking semaglutide 2.4 mg can reduce the likelihood of people with overweight or obesity developing type 2 diabetes, shows further analysis of STEP 1.

Around 44% of the 1961 STEP 1 participants had prediabetes, with an average glycated hemoglobin of 5.9% (41 mmol/mol). During the 68-week trial, those taking semaglutide lost, on average, 13.7% of their baseline bodyweight, which was in line with the 14.9% reduction in the cohort overall.

Reporting the latest findings at the virtual ADA 81st Scientific Sessions, Leigh Perreault (University of Colorado Anschutz Medical Campus, Aurora, USA) revealed that 84.1% of the participants with prediabetes who were taking semaglutide reverted to normoglycemia, compared with 47.8% of those taking placebo.

A corresponding 15.3% versus 49.1% remained in the prediabetic range, and 0.5% versus 3.0% progressed to type 2 diabetes.

Among the people with baseline normoglycemia, 2.9% of those taking semaglutide progressed to prediabetes during the trial, but so did a significantly larger 10.9% of those taking placebo.

Reversion to normoglycemia was closely linked to the amount of weight lost, with rates in the semaglutide group ranging from 65.4% of those who lost less than 5% of their starting bodyweight to 95.3% of those who lost 20% or more. The pattern was the same in the placebo group, although the number of people with significant weight loss was much smaller; for example, three people lost 20% or more, compared with 142 people taking semaglutide.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group

ADA Scientific Sessions; 25–29 June 2021


Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »